Daniel Lee

1.5k total citations
35 papers, 850 citations indexed

About

Daniel Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Daniel Lee has authored 35 papers receiving a total of 850 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Daniel Lee's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (10 papers) and Cancer Genomics and Diagnostics (8 papers). Daniel Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (10 papers) and Cancer Genomics and Diagnostics (8 papers). Daniel Lee collaborates with scholars based in South Korea, United States and Spain. Daniel Lee's co-authors include Joong Sun Lee, Sang Jun Park, Chong Hyun Suh, Dae Chul Suh, J. S. Kim, Sun U. Kwon, Dong‐Wha Kang, Hanjong Ahn, Cheryn Song and Jun Hyuk Hong and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Daniel Lee

35 papers receiving 834 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Lee South Korea 12 631 519 197 101 100 35 850
Keita Kudo Japan 13 611 1.0× 1.0k 2.0× 173 0.9× 100 1.0× 107 1.1× 35 1.3k
Haruko Daga Japan 16 611 1.0× 594 1.1× 181 0.9× 96 1.0× 182 1.8× 92 911
D. H. Lee South Korea 12 670 1.1× 537 1.0× 164 0.8× 94 0.9× 120 1.2× 15 880
Ramón Palmero Spain 14 328 0.5× 384 0.7× 159 0.8× 41 0.4× 79 0.8× 50 646
Reyes Bernabé Spain 19 611 1.0× 684 1.3× 211 1.1× 89 0.9× 173 1.7× 92 1.1k
Yukihiro Toi Japan 10 548 0.9× 1.0k 2.0× 109 0.6× 81 0.8× 49 0.5× 36 1.2k
Fernando C. Santini United States 13 464 0.7× 685 1.3× 211 1.1× 73 0.7× 143 1.4× 34 958
Roman Groisberg United States 14 385 0.6× 442 0.9× 191 1.0× 23 0.2× 167 1.7× 50 742
Sasja F. Mulder Netherlands 12 340 0.5× 253 0.5× 265 1.3× 54 0.5× 130 1.3× 38 669
Dengfeng Ren China 11 346 0.5× 535 1.0× 180 0.9× 71 0.7× 149 1.5× 47 825

Countries citing papers authored by Daniel Lee

Since Specialization
Citations

This map shows the geographic impact of Daniel Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Lee more than expected).

Fields of papers citing papers by Daniel Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Lee. The network helps show where Daniel Lee may publish in the future.

Co-authorship network of co-authors of Daniel Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Lee. A scholar is included among the top collaborators of Daniel Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Lee. Daniel Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Daniel, et al.. (2025). Analysis of Regulatory Botanical Submission Profile for Cancer Management from the U.S. FDA Perspectives. Therapeutic Innovation & Regulatory Science. 59(5). 1129–1137. 1 indexed citations
2.
Lee, Sanghoon, et al.. (2024). Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer. Cancer Immunology Research. 12(3). 287–295. 1 indexed citations
3.
Maguire, William F., Daniel Lee, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(10). 2011–2016. 13 indexed citations
4.
Lee, Daniel, Haley Gittleman, Chana Weinstock, et al.. (2023). A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. European Urology. 84(4). 373–378. 8 indexed citations
5.
6.
Gainor, Justin F., Giuseppe Curigliano, D.-W. Kim, et al.. (2021). MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 16(1). S31–S32. 2 indexed citations
7.
8.
Paz‐Ares, Luis, David Vicente, Enriqueta Felip, et al.. (2020). 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S822–S822. 1 indexed citations
9.
Selvaggi, Giovanni, Heather A. Wakelee, Tony Mok, et al.. (2020). ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3. Journal of Thoracic Oncology. 15(10). e41–e42. 32 indexed citations
10.
Quiroga‐Garza, Gabriela, et al.. (2020). Rare Presentation of Metastatic Lobular Breast Carcinoma Involving Clear Cell Renal Cell Carcinoma. SHILAP Revista de lepidopterología. 2020. 1–5. 4 indexed citations
11.
Perets, Ruth, Jair Bar, Drew Rasco, et al.. (2020). Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Annals of Oncology. 32(3). 395–403. 65 indexed citations
12.
Chun, Sung‐Min, et al.. (2019). P2.01-51 Next-Generation Sequencing for Effective Detection of Various EGFR Exon 20 Insertions (E20ins) in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S659–S659. 4 indexed citations
13.
Yoon, Shinkyo, et al.. (2019). P1.14-53 Co-Occurring CDKN2A/2B Alteration Is Associated with Poorer Survival in ALK-Positive Lung Cancer. Journal of Thoracic Oncology. 14(10). S576–S576. 2 indexed citations
14.
Paz-Ares, L., David Planchard, James Chih‐Hsin Yang, et al.. (2018). MA26.10 CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 13(10). S453–S454. 2 indexed citations
15.
Lee, Daniel. (2018). MS26.01 Translation of Clinical Data to Real World - Asia. Journal of Thoracic Oncology. 13(10). S296–S296. 3 indexed citations
16.
Lee, J.L., Inkeun Park, Daniel Lee, et al.. (2015). RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Annals of Oncology. 26(11). 2300–2305. 86 indexed citations
17.
Sun, Jong‐Mu, Yong Chan Ahn, Eun Kyung Choi, et al.. (2013). Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Annals of Oncology. 24(8). 2088–2092. 76 indexed citations
18.
Zhao, Lin, Hai-Bin Shi, Soonchan Park, et al.. (2013). Acute Bleeding in the Head and Neck: Angiographic Findings and Endovascular Management. American Journal of Neuroradiology. 35(2). 360–366. 26 indexed citations
19.
Suh, Cheolwon, Daniel Lee, Chang‐Ki Min, et al.. (2010). Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Annals of Oncology. 22(2). 411–416. 25 indexed citations
20.
Kang, Chang‐Ki, et al.. (2010). Assessment of Pial Branches Using 7-Tesla MRI in Cerebral Arterial Disease. Cerebrovascular Diseases. 29(4). 410–411. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keita Kudo Breakdown of academic impact, for papers by Haruko Daga Breakdown of academic impact, for papers by D. H. Lee Breakdown of academic impact, for papers by Ramón Palmero Breakdown of academic impact, for papers by Reyes Bernabé Breakdown of academic impact, for papers by Yukihiro Toi Breakdown of academic impact, for papers by Fernando C. Santini Breakdown of academic impact, for papers by Roman Groisberg Breakdown of academic impact, for papers by Sasja F. Mulder Breakdown of academic impact, for papers by Dengfeng Ren
Rankless by CCL
2026